Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 7Recurrence 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasms 1Ganglioneuroblastoma 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × 3-Iodobenzylguanidine × Clear all
NCT01313936 2019-04-29

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

University of California, San Francisco

Phase 1 Completed
32 enrolled 8 charts
CNS

Neoplasms, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡